Guru Sonpavde
古鲁·桑帕夫德
MD
Director, Bladder Cancer Program膀胱癌项目主任
👥Biography 个人简介
Guru Sonpavde directs the bladder cancer program at Dana-Farber, known for pioneering studies on FGFR-targeted therapies, erdafitinib, and novel agents in urothelial carcinoma. He has led multiple clinical trials and meta-analyses establishing evidence-based treatment standards globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FGFR-Targeted Therapy in Bladder Cancer
Contributed to clinical development of erdafitinib and other FGFR inhibitors in FGFR-altered urothelial carcinoma, establishing targeted therapy as a key approach in molecularly selected bladder cancer patients.
Systemic Therapy Meta-analyses
Conducted comprehensive meta-analyses of chemotherapy and immunotherapy regimens in urothelial carcinoma, providing high-level evidence to inform treatment guidelines and clinical practice recommendations.
Representative Works 代表性著作
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
New England Journal of Medicine (2019)
Phase II trial leading to first FDA-approved targeted therapy for FGFR-altered metastatic urothelial carcinoma.
Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis
European Urology (2020)
Comprehensive meta-analysis defining efficacy and safety benchmarks for checkpoint inhibitors in urothelial carcinoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 古鲁·桑帕夫德 的研究动态
Follow Guru Sonpavde's research updates
留下邮箱，当我们发布与 Guru Sonpavde（Dana-Farber Cancer Institute, Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment